A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.
EP. 1: Phase 3 SELECT Trial Overview
EP. 2: SELECT Trial: Toxicity, Duration of Response, and Dose Reduction
EP. 3: What is Radioiodine-Refractory DTC?
EP. 4: Radioiodine-Refractory DTC: NCCN Guidelines
EP. 5: Multikinase Inhibitor Overall Survival Advantage
2 Clarke Drive Cranbury, NJ 08512